<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02522104</url>
  </required_header>
  <id_info>
    <org_study_id>SIK-FR 14-1</org_study_id>
    <nct_id>NCT02522104</nct_id>
  </id_info>
  <brief_title>Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)</brief_title>
  <official_title>Evaluation of the Impact of Renal Function on the Pharmacokinetics of Hydroxyurea (SIKLOS ®) in Normal-renal Function, Hyperfiltrating and Renal Failure Sickle Cell Disease Patients (DARH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ADDMEDICA SASA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ADDMEDICA SASA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of hydroxyurea in sickle cell disease patients with glomerular hyperfiltration and
      renal failure requires a specific monitoring and dose adjustment in order to remain within
      the therapeutic interval while limiting the risk of toxicity or therapeutic failure. For this
      reason the investigators propose to compare the pharmacokinetic parameters of hydroxyurea in
      normal-renal function sickle cell patients to those of patients with glomerular
      hyperfiltration or moderate renal failure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2015</start_date>
  <completion_date type="Actual">November 28, 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of plasmatic data: maximum concentration (Cmax)</measure>
    <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of plasmatic data: minimum concentration (Cmin)</measure>
    <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of plasmatic data: time to obtain the maximum concentration (Tmax)</measure>
    <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of plasmatic data: area under the curve (AUC0-24)</measure>
    <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of plasmatic data: elimination half-life (T½)</measure>
    <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of plasmatic data: total clearance (Cl tot)</measure>
    <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of plasmatic data: distribution volume</measure>
    <time_frame>0 hour, 0.75 hour, 1.5 hours, 3 hours, 4 hours, 6 hours, 7.5 hours , 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of urinary data: hydroxyurea urinary fractions</measure>
    <time_frame>From 0 to 4 hours, 4 to 7.5 hours and 7.5 to 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of urinary data: renal clearance (Cl renal).</measure>
    <time_frame>From 0 to 4 hours, 4 to 7.5 hours and 7.5 to 24 hours</time_frame>
    <description>Compare the pharmacokinetic parameters of hydroxyurea in normal-renal function sickle cell patients to those of patients with glomerular hyperfiltration or moderate renal failure</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Renal Function Disorder</condition>
  <arm_group>
    <arm_group_label>Normal-renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal-renal function: 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glomerular hyperfiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glomerular renal hyperfiltration: GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140 mL/min/1.73m2 in men.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate renal failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate renal failure: 30 ≤ GFR ≤ 60 mL/min/1.73m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Siklos</intervention_name>
    <arm_group_label>Normal-renal function</arm_group_label>
    <arm_group_label>Glomerular hyperfiltration</arm_group_label>
    <arm_group_label>Moderate renal failure</arm_group_label>
    <other_name>hydroxyurea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Male or female.

          -  Sickle cell disease (SS or S-β0thal) confirmed by haemoglobin electrophoresis and
             genotyping by deoxyribonucleic acid (DNA) analysis.

          -  Affiliation to a social security system.

          -  Having freely consented in writing after being informed of the objective, programme
             and potential risks incurred.

        These criteria will apply to the 3 groups of sickle cell disease patients according to the
        renal function stage defined by the glomerular filtration rate (GFR) estimated by the
        formula of the Chronic Kidney Disease EPIdemiology (CKD EPI) collaboration without ethnic
        criterion during the last 6 months before inclusion:

          -  Normal-renal function: 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in
             men.

          -  Moderate renal failure: 30 ≤ GFR ≤ 60 mL/min/1.73m2.

          -  Glomerular renal hyperfiltration: GFR &gt; 130 mL/min/1.73m2 in women and GFR &gt; 140
             mL/min/1.73m2 in men.

               -  Treated with hydroxyurea (Siklos®) with a stable dosage for at least one week ± 2
                  days before inclusion in the study and dose administered in the morning at 9:00 ±
                  15 minutes.

        Exclusion Criteria:

          -  Refusal to consent.

          -  Patients that do not comply.

          -  Occurrence of vaso-occlusive crisis in the month prior to the inclusion in the study.

          -  Patients having had an exchange transfusion in the 15 days before inclusion in the
             study.

          -  Patients participating in another clinical trial or in the exclusion period of a
             previous clinical trial.

          -  Patients treated with a diuretic.

          -  Dialysis patient.

          -  Patients with an intercurrent disorder, especially inflammatory, that has not
             recovered for at least one month.

          -  Pregnant or breast-feeding women.

          -  Patients deprived of liberty or under legal protection.

          -  Patients who cannot understand the objective and the course of the study, incapable of
             giving their consent.

          -  In the event of severe hepatic failure.

          -  In the event of severe renal failure (creatinine clearance &lt; 30 ml/min).

          -  Patients who show toxic signs of bone marrow suppression.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BARTOLUCCI Pablo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Référence des Syndromes Drépanocytaires Majeurs, Hôpital Henri-Mondor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Référence des Syndromes Drépanocytaires Majeurs, Hôpital Henri-Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics of Hydroxyurea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

